CareFusion Launches New ChloraPrep® Applicator For Smaller Coverage Areas

ChloraPrep 1 mL Applicator Provides Additional Option to Proven Portfolio of Patient Skin Preparation Products

News provided by

Jul 31, 2014, 08:30 ET

SAN DIEGO, July 31, 2014 /PRNewswire/ -- CareFusion (NYSE:CFN), a leading global medical technology company, today announced the launch of its ChloraPrep^® 1 mL applicator, the newest addition to the ChloraPrep line of preoperative skin preparation products.

ChloraPrep 1 mL provides clinicians with a preferred applicator design and the same formulation as all other ChloraPrep applicators but in a new 1 mL size. The new size is ideal for procedures with an application area approximately 2.5 inches by 2.5 inches or smaller.

"The new ChloraPrep 1 mL applicator is an excellent extension of our ChloraPrep family of products, using the same formulation clinicians have come to know and trust," said Jan Creidenberg, vice president and general manager of Infection Prevention for CareFusion. "We continue to extend our skin prep leadership through our commitment to innovation and new product development to better meet our customers' needs."

With its unique delivery system and winged activation design, the 1 mL applicator is easy to use and can help promote aseptic technique and best practices. ChloraPrep skin prep products have been proven to be more effective than povidone-iodine at reducing microorganisms on the skin that may cause infection.¹²³ChloraPrep chlorhexidine products also have a low incidence of irritation and maintain their antimicrobial effectiveness in the presence of blood, unlike iodine-based products.⁴

Clinicians interested in trying the new ChloraPrep 1 mL applicator can visit carefusion.com/SmallButBig and fill out a form to request a sample.

About CareFusion Corporation
CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops industry-leading technologies including Alaris^® infusion pumps and IV sets, MaxPlus^® and MaxZero^™ IV connectors and sets, Pyxis^® automated dispensing and patient identification systems, AVEA^®, LTV^® series and AirLife^®ventilation and respiratory products, ChloraPrep^® products, MedMined^® services for data mining surveillance, V. Mueller^® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs approximately 15,000 people across its global operations. More information may be found at www.carefusion.com.

¹Saltzman MD, Nuber GW, Gryzlo SM, Marecek GS, Koh JL. Efficacy of surgical preparation solutions in shoulder surgery. J Bone Joint Surg Am. 2009;91(8):1949–1953.
²Ostrander RV, Botte MJ, Brage ME. Efficacy of surgical preparation solutions in foot and ankle surgery. J Bone Joint Surg Am. 2005;87(5):980–985.
³Adler MT, Brigger KR, Bishop KD, Mastrobattista JM. Comparison of bactericidal properties of alcohol-based chlorhexidine versus povidone-iodine prior to amniocentesis. Am J Perinatol. 2012;29(6):455–458. Epub 2012 Mar 7.
⁴Denton, G. Chlorhexidine. In Block, SS. Disinfection, Sterilization, and Preservation, 5th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:321–336.

Logo - http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO

SOURCE CareFusion